The frequency and type of p53 gene mutations was investigated in a series of 5 2 cases of multiple myeloma (MM) representative of the different clinical phases and forms of the disease (indolent, 1 2 cases; chronic, 24 cases; acute/ leukemic, 1 6 cases). DNAs were analyzed for p53 gene mutations in exons 5 to 9 by polymerase chain reaction (PCR), single-strand conformation polymorphism (SSCP), and direct sequencing of PCR-amplified fragments. Point mutations were detected in 7 of 5 2 patients (13%) (5 at exon 8; 1 at exon 6; 1 at exon 7). and were specifically associated with the more advanced and clinically aggressive ULTIPLE MYELOMA (MM) is a malignant prolif-M eration of bone marrow plasma cells of uncertain etiopathogenesis, characterized by a spectrum of clinical entities, including localized and disseminated indolent and aggressive forms.' These clinical forms frequently occur sequentially during the clinical course of MM (from indolent to chronic and acutefleukemic phases), suggesting that the development of MM is a multistep process in which genetic events, such as oncogene activation, are responsible for its progression into more advanced and clinically aggressive forms. No specific association with alterations of known proto-oncogene loci has yet been established. We have recently reported that RAS oncogenes (predominantly N-RAS and less frequently K-RAS) are activated in vivo in about 30% of cases of MM. RAS mutations were present in patients at different clinical stages, although RAS oncogenes were more frequently observed in patients relapsing after treatment with alkylating agents; in the same series of patients, no rearrangements or mutations were found in the c-myc protooncogene IOCUS.~ Alterations of the p53 tumor suppressor gene are involved in various types of human cancers, particularly colon, breast, brain, lung, and liver Loss of the normal growth-inhibitor activity of the p53 gene in most of these tumors occurs as a result of point mutations of one p53 allele associated with the loss of the other p53 allele. However, the presence in some tumors of both the normal and the mutated p53 allele,3-5 as well as experimental evidence indicating that some p53 mutant alleles can transform in vitro target cells 1 6 [43%] .) Three of the mutated cases had been evaluated at clinical presentation in earlier phases of the disease (indolent or chronic) and were found to be negative for p53 mutation. Moreover, three patients with p53 mutation had not received chemotherapy at the time of investigation. These results support the notion that the development of MM is a multistep process and suggest that alterations in the p53 gene may represent an important late event in MM tumor progression.
even in the presence of a normal suggests that in some cases p53 may act as a dominant-negative oncogene. The majority of mutations occur in the p53 gene region between codons l 10 and 307 encompassing exons 5 to 9" and are clustered in four regions representing four domains of the p53 coding sequence that are highly conserved among several different species. l4 In the context of hematologic malignancies, an appreciable frequency of p53 mutations has been recently observed in Burkitt's lymphoma (BL), L3-type B-acute lymphoblastic leukemia (L3-type B-ALL), and chronic lymphocytic leukemia (B-CLL), but not in cases of non-Hodgkin's lymphoma (NHL) and only occasionally in peripheral T-cell lymphoma and hairy cell leukemia (HCL).I5 A low frequency of p53 mutations has been reported in acute myeloid leukemias (AML) 16 and in myelodysplastic syndromes (MDS). " We report here our investigations of the frequency and type of p53 gene mutations in a relatively large series of MM patients representative of the different forms and phases of the disease. The results show that p53 mutations are frequently found in patients with MM and are associated with the more advanced (acute/leukemic) forms of the disease.
MATERIALS AND METHODS
Pathologic samples and DNA preparation. Bone marrow aspirates from 52 patients were collected during standard diagnostic procedures. The diagnosis and clinical staging of MM were made according to the criteria described by Dune and Salmon." Patients were classified into three different groups based on clinical and laboratory parameters, and duration of survival19: A (indolent, 12 cases); B (chronic, 24 cases); C (acute/leukemic, 16 cases) ( Table 1) . Group A included patients in stage I with asymptomatic disease for at least 1 year. Group B included patients with symptomatic disease in stage I1 or 111, nine of which have received chemotherapy. Group C included six patients with acute MM and I O patients with plasma cell leukemia (PCL). The diagnosis of PCL was made according to the criteria of Kyle et aLzo In our series, four patients presented de novo PCL, one showed PCL after a previous phase of indolent MM, and five patients were in relapse after a chronic phase. All of the patients with acute MM were resistant to therapy and presented bone marrow failure (hemoglobin [Hb] , 43.5 g/dL; platelet count, <IO0 X 109/L) related to the high percentage of plasma cell infiltration (>50%) with blastic features. Their survival duration ranged from 1 to 9 months. Three ofthe patients in group C had been evaluated at presentation as being in indolent ( Oncology Group (SWOG) criteria were used to evaluate treatment response or relapse.2' Mononuclear cell suspensions of greater than 95% viability from bone marrow aspirates were prepared by Ficoll-Hypaque gradient centrifugation. In all cases, the percentage of malignant plasma cells determined by immunocytomorphologic analysis was between 22% and 98% ofthe total bone marrow mononuclear cell population ( Table  2) . DNA was purified by proteinase K digestion, extraction with phenol-chloroform, and ethanol precipitation.22
Ten micrograms of DNA from each sample was digested to completion with Hind111 or EcoRI restriction enzymes, size fractionated in 0.7% agarose gel, and tranferred to Hybond-N+ nylon filters (Amersham, Amersham, UK). Blots were hybridized with random primer 3ZP-labeled probes according to the manufacturer's specifications, washed in 0.5% SSC/ 1 % sodium dodecyl sulfate (SDS) for l hour at 60°C, and autoradiographed at -70°C. If enough material was available, additional digestion with BamHI restriction enzyme was performed. IgH gene rearrangements were detected with the 6.6-kb BamHI-Hind111 fragment representative of the joining (JH) regi0n.2~ Rearrangements of the Igk gene were studied using the 1.8-kb Sac I-Sac I fragment specific of the joining (Jk) region,z4 and X gene rearrangements were studied using the 0.7-kb Bgl 11-EcoRI fragment specific for the constant (CX) region.z3
Polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCFj analysis. The oligonucleotide primers used to amplify p53 exons 5 to 9 have been previously reported" and were purchased from Beckman Analytical (Milan, Italy). SSCP analysis was performed using a modified version of the method originally described by Orita et al. 25 Briefly, PCR was performed using 100 ng ofgenomic DNA, 5 pmol of each primer, 2.5 mmol/L dNTPs, 1 WCi Southern blot analysis.
of [a-"P]dCTP, 10 mmol/L Tris-HC1 (pH 8.Q 50 mmol/L KCI, I mmol/L MgCl2, 0.01% gelatin, 0.5 U Taq polymerase (Boehringer Mannheim, Mannheim, Germany) in a final volume of 10 wL. Thirty cycles of denaturation (15 seconds at 94"C), annealing (1 minute at 65°C for reactions amplifying exons 5, 6, 7, and 9; 58°C for exon 8), and extension (1 minute at 72°C) were performed on an automated heat-block (Perkin-Elmer Cetus, Nonvalk, CT). The reaction mixture (4 pL) was diluted 1 :25 in 0.1 % NaDodS04-10 mmol/L EDTA and 1: 1 mixed with a sequencing stop solution containing 20 mmol/L NaOH. Samples were heated at 95°C for 5 minutes, chilled on ice, and immediately loaded (4 pL) onto a 690 acrylamide-TBE gel containing 10% glycerol. Gels were run at 8 W for 12 to 15 hours at room temperature, fixed in 10% acetic acid, and air dried. Autoradiography was performed using an intensifying screen overnight at PCR was performed using 1 pg of genomic DNA, 20 pmol of each primer, 200 mmol/L dNTPs, 10 mmol/L Tris-HC1 (pH 8.Q 50 mmol/L KCI, 1 mmol/L MgC12, 0.0190 gelatin, and 2.5 U of Taq polymerase in a final volume of 50 pL. The number and conditions of amplification cycles were the same as described above for each pair of primers. For direct sequencing, one of the two primers used for DNA amplification was used. Direct DNA sequencing of the amplified fragment was performed as previously described.26 -80°C.
Direct sequencing of PCR-amplij5ed fragments. Mutations detected by SSCP analysis were found in 7 of 52 cases (13%). As shown in Fig 3, mutations occurred at exon 6 in case LB 4 18, at exon 7 in case LB 38 1, and at exon 8 in cases LB 417, LB 31, LB 145, LB 76, and LB 375. To confirm the data obtained by PCR/SSCP analysis further, and to determine the exact nature of the mutation in the positive cases, the nucleotide sequence of the involved exons was investigated by direct sequencing analysis of the PCR products (Fig 4) . In all seven cases, p53 mutations were represented by a single nucleotide change with a missense mutation resulting in amino acid substitution (Table 2 ). In two cases (LB 145 and LB 381), mutations occurred at CpG dinucleotides in the form of C to T transition; in the remaining cases, mutations did not involve CpGs and occurred in the form of G to A or T to C transitions (LB 76, LB 3 1, and LB 3 7 3 , or A to T tranversion (LB 418). All mutations were found within the p53 gene regions showing high homology among different species, or in their immediate vicinity (mutation at codon 193 in case LB 418). In three cases (LB 31, For LB 38 1, and LB 4 17), the absence of the wild-type sequence presumably reflected the loss of the normal allele. In cases LB 76 and LB 375, in which the percentage of malignant plasma cells was, respectively, 92% and 98% (Table 2) , the presence of the wild-type sequence may reflect p53 heterozygosity of the tumor cells. In cases LB 145 and LB 418, the presence of an appreciable fraction of normal contaminating cells makes it impossible to draw any conclusion. In cases LB 76, LB 145, LB 375, and LB 41 8, it seems that the relative levels of mutant to wild-type bands in direct sequencing do not correlate with the pattern observed in SSCP. This discrepancy may reflect the specific technical characteristics of the two methods; in particular, the band intensity in the sequencing ladder may be. related to the nucleotide composition of the sequence.22 % Jurkat 
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Clinical correlations. p53 mutations in patients with MM were associated with the more aggressive forms of the disease ( Table 2) . In fact, mutations were detected in 7 of 16 (43%) patients in the acute or leukemic phase (group C), but in none of the patients in the indolent or chronic phase (groups A and B). Interestingly, in three cases carrying p53 mutation, the presence of mutation was investigated at clinical presentation when the patients were in indolent (case LB 375) or chronic phase (cases LB 145 and LB 417), but no p53 mutation was observed at that time (data not shown). The percentage of plasma cells in mononuclear cell suspension obtained from these three cases in the earlier phase of the disease was, respectively, 28%, 49%, and 75%. Table 3 . However, despite the relatively small sample size, two elements did emerge from this analysis: ( I ) patients with p53 mutations seem to have a shorter median survival than that of patients negative for mutations (3 v 6 months): (2) only 3 of IO patients(3Wo) in the leukemic phase were positive for p53 mutation.
DISCUSSION
The aim of this study was to investigate the frequency and type of p53 gene mutations in a series of MM cases representative of the different clinical forms and phases of the primer used for PCR amplification was also used as sequencing primer. Each sequence is shown 5' (top) to 3' (bottom). The nucleotide sequence corresponding to human placenta DNA (normal) is reported and the codons at which the mutation occurred are boxed. Bands corresponding to the mutated base pairs are indicated by arrows. The extra bands visible from the top in case LB 31, as well as in case 41 7, are probably related to the q u a l i of the DNA template or the noncomplete denaturation of DNA during electrophoresis in our experimental conditions. Point mutations involving the p53 gene were found in 7 of 52 MM patients ( I 3%). This percentage can be considered as reasonably accurate for the following reasons. Firstly, mutations occuning outside the regions we investigated have 
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Since the time of the study rearrangement analysis2ss29 showed more than 20% of malignant plasma cells in our samples, which is higher than the threshold of sensitivity of SSCP analysis under our experimental conditions.
The mutations reported in our study occurred in regions of the p53 protein that are highly conserved among different species, and are likely to be essential for its biologic activity and interactions with other cellular and viral proteins.14 All of the mutations have already been reported in other types of tumors" except, as far we know, that of codon 275 (found in case LB 375). In this case, the mutation was close to the well-documented mutational "hot spot" of codon 273, and it is worth noting that it was absent in a pathologic sample from the same patient obtained during the indolent phase of the disease. All of these observations suggest that the p53 gene mutations detected in MM patients play a pathologic role and represent somatic events related to the process of tumorigenesis.
The occurrence of p53 mutations in human cancer is presumably the consequence of several mutagenic factors that may act specifically in a particular type of tumor. A notable finding of p53 mutations in human cancer is the transitions at CpG dinucleotides occumng in about one-third of tumors (mainly colon carcinomas); in lung and liver carcinomas, G to T transversions are predominantly found. " CpG dinucleotides represent a target of spontaneously arising mutations in mammalian cells because of the presence of 5-methylcytosine residues. Given the limited number of mutations detected in our study, it is difficult to suggest any possible mechanism for the occurrence of mutations in MM; only two of seven mutations occurred at CpGs in the form of C to T transition. However, it is important to note that the majority of mutations in MM (5 of 7) fell within domain V of the p53 gene (codons 270 to 286). This intriguing finding may reflect the possibly selective nature of these changes and suggests, among several other possibilities, the involvement of a particular, albeit unknown mutagen or a selective advantage conferred in vivo to malignant plasma cells by a particular mutated p53 protein.
A number of observations derived from the analysis of different types of human tumors indicate a correlation between p53 mutations and neoplastic progression. In colon carcinomas, p53 mutations and 17p allelic deletions represent late events in colorectal tumorigenesis, generally occumng at the time of transition from adenoma to invasive carcinoma. 4 In B-CLL, p53 mutations appear to be more frequent in Richter's syndrome, which represents the evolution of B-CLL into a more advanced and clinically aggressive form.15 It has recently been reported that clonal expansion of cells carrying p53 mutations is associated with brain tumor progres~ion,~' strongly supporting the general observation that p53 mutation is a crucial step in the progression from lowgrade to high-grade tumors. The direct outcome ofthe results shown in the present study is the association of p53 mutations with the more advanced and aggressive forms of MM (7 of 16 [43%]). No p53 mutations were found in patients with indolent or chronic disease and, even more interestingly, p53 mutation was not detected in any of the three positive cases (LB 375, LB 417, and LB 145) first tested at clinical presentation in indolent or chronic phase. These findings may reflect a specific involvement of p53 in the later stages of MM or the mutagenic effect of certain chemotherapeutic agents. However, as far as this last possibility is concerned, it should be noted that three of the seven patients carrying p53 mutations had not received chemotherapy at the time of this study and, on the other hand, 14 patients negative for mutation (9 in chronic phase and 5 in acute/leukemic phases) had received chemotherapy. Taken together, these observations strongly suggest that p53 mutations may represent one of the genetic events leading to tumor progression in MM.
Despite the suggested important role of p53 mutations in the neoplastic progression of MM, our observation that mutations are specifically associated with the acute or leukemic forms of MM, and are completely absent in the indolent and chronic forms, could limit the possible importance of p53 mutation as a clinico-prognostic marker in this neoplasm. Acute and leukemic forms represent the final stage of MM and are well defined by a number of clinico-hematologic crk teria.I9 Patients in these clinical phases generally have a bad prognosis with a poor therapeutic response and brief survival. Nevertheless, it is interesting that, among the patients in the acute or leukemic phase, those carrying p53 mutation have a shorter survival than patients negative for mutation, suggesting that the presence of p53 mutation may identify a particular subgroup of patients. Further studies involving larger series of patients are necessary to confirm the pathogenetic and clinical implications of p53 mutations in MM.
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